Last week MJH Life Scienceshosted the first installment of its three-part webinar series, “ The Most Favored Nation Mandate: What the President’s Drug Pricing Push Means for Pharma, Payers, and Patients .” The roundtable discussion featured Brian Corvino, principal and global market access practice leader at Deloitte US; Neal Masia, Ph.D., co-founder and CEO of EntityRisk, Inc., and founder of Health Capital Group, LLC; Ali Pashazadeh, founder, chairman and CEO of Treehill Partners; and George Van Antwerp, MBA, senior vice president of product innovation and strategic planning at Prime Therapeutics.

MFN drug pricing may just be the opening bid in the White House’s negotiations with pharma

The White House issued its first most-favored nation drug pricing order in May, and President Dona

See Full Page